May 19, 2022 7:00 am EDT Ocuphire Announces Positive Topline Results from LYNX-1 Phase 3 Trial Evaluating Nyxol® Eye Drops for Night Vision Disturbances
May 13, 2022 8:00 am EDT Ocuphire Pharma Announces Financial Results for First Quarter 2022 and Provides Corporate Update
May 11, 2022 8:00 am EDT Ocuphire Pharma Announces Upcoming Presentations at the Retina World Congress, Clinical Trials at the Summit, and the H.C. Wainwright Global Investment Conference
May 4, 2022 4:05 pm EDT Opus Genetics Announces Promising New Data Highlighting Potential of AAV-based Gene Therapies for the Treatment of Rare Inherited Retinal Diseases
Apr 28, 2022 8:00 am EDT New Data on Potential of Opus AAV-based Gene Therapies for Rare Inherited Retinal Diseases to be Presented at Association for Research in Vision and Ophthalmology Annual Meeting 2022
Apr 28, 2022 7:00 am EDT Ocuphire Completes Last Clinical Trial Supporting the Planned 2022 NDA Submission with the Announcement of Positive Results from MIRA-4 Pediatric Safety Trial Evaluating Nyxol® for Reversal of Mydriasis
Apr 26, 2022 9:00 am EDT Ocuphire Announces Upcoming Clinical Presentations at ARVO 2022 Medical Meeting and MODLive! 2022
Apr 11, 2022 8:00 am EDT Opus Enters Strategic Collaboration with Resilience for AAV-based Gene Therapy Development and Manufacturing for Inherited Retinal Diseases
Apr 6, 2022 8:00 am EDT Ocuphire Pharma to Present at Wet AMD & DME Drug Development Summit in Boston, MA